glp 1 agonists in development GLP-1 Receptor Agonist Market Size GLP-1 Receptor Agonist Services for
Description
Incretin mimetics considerably expanded their proven benefits beyond obesity in 2024
The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs
Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results
Download it once and read it on your Kindle device, PC, phones or tablets
